nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—Progesterone Congeners—Medroxyprogesterone Acetate—uterine cancer	0.288	1	CiPCiCtD
Levonorgestrel—Progesterone—uterine cancer	0.206	1	CrCtD
Levonorgestrel—PGR—uterine cancer	0.0589	0.432	CbGaD
Levonorgestrel—CYP19A1—uterine cancer	0.0404	0.296	CbGaD
Levonorgestrel—ESR1—uterine cancer	0.0372	0.272	CbGaD
Levonorgestrel—PGR—Medroxyprogesterone Acetate—uterine cancer	0.0263	0.169	CbGbCtD
Levonorgestrel—SHBG—Medroxyprogesterone Acetate—uterine cancer	0.0253	0.163	CbGbCtD
Levonorgestrel—AR—Medroxyprogesterone Acetate—uterine cancer	0.0212	0.136	CbGbCtD
Levonorgestrel—ESR1—Medroxyprogesterone Acetate—uterine cancer	0.0183	0.118	CbGbCtD
Levonorgestrel—PGR—Progesterone—uterine cancer	0.0175	0.112	CbGbCtD
Levonorgestrel—SHBG—Progesterone—uterine cancer	0.0168	0.108	CbGbCtD
Levonorgestrel—Ethynodiol—Medroxyprogesterone Acetate—uterine cancer	0.0148	0.104	CrCrCtD
Levonorgestrel—AR—Progesterone—uterine cancer	0.014	0.0901	CbGbCtD
Levonorgestrel—Nandrolone phenpropionate—Progesterone—uterine cancer	0.0137	0.0965	CrCrCtD
Levonorgestrel—Nandrolone decanoate—Progesterone—uterine cancer	0.0137	0.0965	CrCrCtD
Levonorgestrel—Ethynodiol—Progesterone—uterine cancer	0.0129	0.0905	CrCrCtD
Levonorgestrel—Norgestimate—Progesterone—uterine cancer	0.0129	0.0905	CrCrCtD
Levonorgestrel—ESR1—Progesterone—uterine cancer	0.0121	0.0779	CbGbCtD
Levonorgestrel—Danazol—Progesterone—uterine cancer	0.00877	0.0617	CrCrCtD
Levonorgestrel—Norethindrone—Progesterone—uterine cancer	0.00763	0.0537	CrCrCtD
Levonorgestrel—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	0.00737	0.0518	CrCrCtD
Levonorgestrel—Progesterone—Medroxyprogesterone Acetate—uterine cancer	0.00737	0.0518	CrCrCtD
Levonorgestrel—Methyltestosterone—Medroxyprogesterone Acetate—uterine cancer	0.00718	0.0505	CrCrCtD
Levonorgestrel—Testosterone Propionate—Progesterone—uterine cancer	0.00642	0.0452	CrCrCtD
Levonorgestrel—Testosterone—Medroxyprogesterone Acetate—uterine cancer	0.00639	0.045	CrCrCtD
Levonorgestrel—Methyltestosterone—Progesterone—uterine cancer	0.00626	0.044	CrCrCtD
Levonorgestrel—Hydrocortisone—Medroxyprogesterone Acetate—uterine cancer	0.00601	0.0423	CrCrCtD
Levonorgestrel—Testosterone—Progesterone—uterine cancer	0.00557	0.0392	CrCrCtD
Levonorgestrel—Hydrocortisone—Progesterone—uterine cancer	0.00524	0.0368	CrCrCtD
Levonorgestrel—PGR—corpus luteum—uterine cancer	0.00206	0.129	CbGeAlD
Levonorgestrel—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.00188	0.0121	CbGbCtD
Levonorgestrel—CYP19A1—corpus luteum—uterine cancer	0.00185	0.116	CbGeAlD
Levonorgestrel—CYP3A4—Progesterone—uterine cancer	0.00124	0.008	CbGbCtD
Levonorgestrel—SHBG—semen—uterine cancer	0.00107	0.067	CbGeAlD
Levonorgestrel—CYP19A1—semen—uterine cancer	0.000868	0.0544	CbGeAlD
Levonorgestrel—AR—semen—uterine cancer	0.000768	0.0481	CbGeAlD
Levonorgestrel—PGR—oviduct—uterine cancer	0.000707	0.0443	CbGeAlD
Levonorgestrel—AR—oviduct—uterine cancer	0.000563	0.0353	CbGeAlD
Levonorgestrel—CYP3A4—Etoposide—uterine cancer	0.000557	0.00358	CbGbCtD
Levonorgestrel—ESR1—oviduct—uterine cancer	0.000553	0.0346	CbGeAlD
Levonorgestrel—SRD5A1—renal system—uterine cancer	0.000502	0.0315	CbGeAlD
Levonorgestrel—PGR—artery—uterine cancer	0.000468	0.0293	CbGeAlD
Levonorgestrel—SRD5A1—female reproductive system—uterine cancer	0.000402	0.0252	CbGeAlD
Levonorgestrel—CYP3A4—Doxorubicin—uterine cancer	0.00038	0.00244	CbGbCtD
Levonorgestrel—PGR—myometrium—uterine cancer	0.000226	0.0142	CbGeAlD
Levonorgestrel—AR—myometrium—uterine cancer	0.00018	0.0113	CbGeAlD
Levonorgestrel—PGR—epithelium—uterine cancer	0.000178	0.0111	CbGeAlD
Levonorgestrel—ESR1—myometrium—uterine cancer	0.000177	0.0111	CbGeAlD
Levonorgestrel—SHBG—endometrium—uterine cancer	0.000177	0.0111	CbGeAlD
Levonorgestrel—PGR—uterine cervix—uterine cancer	0.000176	0.011	CbGeAlD
Levonorgestrel—PGR—smooth muscle tissue—uterine cancer	0.000171	0.0107	CbGeAlD
Levonorgestrel—PGR—decidua—uterine cancer	0.000168	0.0105	CbGeAlD
Levonorgestrel—SHBG—uterus—uterine cancer	0.000163	0.0102	CbGeAlD
Levonorgestrel—PGR—endometrium—uterine cancer	0.000159	0.00998	CbGeAlD
Levonorgestrel—PGR—uterus—uterine cancer	0.000147	0.00919	CbGeAlD
Levonorgestrel—SHBG—female reproductive system—uterine cancer	0.000146	0.00917	CbGeAlD
Levonorgestrel—CYP19A1—endometrium—uterine cancer	0.000143	0.00898	CbGeAlD
Levonorgestrel—AR—epithelium—uterine cancer	0.000141	0.00886	CbGeAlD
Levonorgestrel—AR—uterine cervix—uterine cancer	0.00014	0.00879	CbGeAlD
Levonorgestrel—ESR1—epithelium—uterine cancer	0.000139	0.0087	CbGeAlD
Levonorgestrel—ESR1—uterine cervix—uterine cancer	0.000138	0.00863	CbGeAlD
Levonorgestrel—AR—smooth muscle tissue—uterine cancer	0.000136	0.00854	CbGeAlD
Levonorgestrel—ESR1—smooth muscle tissue—uterine cancer	0.000134	0.00838	CbGeAlD
Levonorgestrel—AR—decidua—uterine cancer	0.000134	0.00837	CbGeAlD
Levonorgestrel—SHBG—female gonad—uterine cancer	0.000133	0.00835	CbGeAlD
Levonorgestrel—SHBG—vagina—uterine cancer	0.000132	0.0083	CbGeAlD
Levonorgestrel—CYP19A1—uterus—uterine cancer	0.000132	0.00827	CbGeAlD
Levonorgestrel—PGR—female reproductive system—uterine cancer	0.000132	0.00826	CbGeAlD
Levonorgestrel—AR—renal system—uterine cancer	0.000131	0.00822	CbGeAlD
Levonorgestrel—ESR1—decidua—uterine cancer	0.000131	0.00822	CbGeAlD
Levonorgestrel—ESR1—renal system—uterine cancer	0.000129	0.00807	CbGeAlD
Levonorgestrel—AR—endometrium—uterine cancer	0.000127	0.00795	CbGeAlD
Levonorgestrel—ESR1—endometrium—uterine cancer	0.000125	0.0078	CbGeAlD
Levonorgestrel—AR—mammalian vulva—uterine cancer	0.000123	0.00769	CbGeAlD
Levonorgestrel—PGR—female gonad—uterine cancer	0.00012	0.00752	CbGeAlD
Levonorgestrel—PGR—vagina—uterine cancer	0.000119	0.00747	CbGeAlD
Levonorgestrel—CYP19A1—female reproductive system—uterine cancer	0.000119	0.00744	CbGeAlD
Levonorgestrel—AR—uterus—uterine cancer	0.000117	0.00732	CbGeAlD
Levonorgestrel—ESR1—uterus—uterine cancer	0.000115	0.00719	CbGeAlD
Levonorgestrel—CYP19A1—female gonad—uterine cancer	0.000108	0.00677	CbGeAlD
Levonorgestrel—AR—female reproductive system—uterine cancer	0.000105	0.00658	CbGeAlD
Levonorgestrel—ESR1—female reproductive system—uterine cancer	0.000103	0.00646	CbGeAlD
Levonorgestrel—AR—female gonad—uterine cancer	9.56e-05	0.00599	CbGeAlD
Levonorgestrel—AR—vagina—uterine cancer	9.51e-05	0.00595	CbGeAlD
Levonorgestrel—ESR1—female gonad—uterine cancer	9.39e-05	0.00588	CbGeAlD
Levonorgestrel—ESR1—vagina—uterine cancer	9.33e-05	0.00585	CbGeAlD
Levonorgestrel—Ethynodiol—PGR—uterine cancer	8.94e-05	0.0669	CrCbGaD
Levonorgestrel—Norelgestromin—PGR—uterine cancer	8.45e-05	0.0632	CrCbGaD
Levonorgestrel—Allylestrenol—PGR—uterine cancer	8.45e-05	0.0632	CrCbGaD
Levonorgestrel—Desogestrel—PGR—uterine cancer	8.13e-05	0.0608	CrCbGaD
Levonorgestrel—PGR—lymph node—uterine cancer	7.72e-05	0.00483	CbGeAlD
Levonorgestrel—Norgestimate—PGR—uterine cancer	7.6e-05	0.0569	CrCbGaD
Levonorgestrel—CYP3A4—renal system—uterine cancer	7.19e-05	0.0045	CbGeAlD
Levonorgestrel—Danazol—CCL2—uterine cancer	6.96e-05	0.0521	CrCbGaD
Levonorgestrel—CYP19A1—lymph node—uterine cancer	6.95e-05	0.00435	CbGeAlD
Levonorgestrel—Quinestrol—ESR1—uterine cancer	6.86e-05	0.0513	CrCbGaD
Levonorgestrel—Etonogestrel—PGR—uterine cancer	6.58e-05	0.0492	CrCbGaD
Levonorgestrel—Nandrolone phenpropionate—CYP19A1—uterine cancer	6.33e-05	0.0474	CrCbGaD
Levonorgestrel—AR—lymph node—uterine cancer	6.15e-05	0.00385	CbGeAlD
Levonorgestrel—ESR1—lymph node—uterine cancer	6.04e-05	0.00378	CbGeAlD
Levonorgestrel—CYP3A4—female reproductive system—uterine cancer	5.76e-05	0.00361	CbGeAlD
Levonorgestrel—Ethynodiol—ESR1—uterine cancer	5.65e-05	0.0422	CrCbGaD
Levonorgestrel—Allylestrenol—ESR1—uterine cancer	5.33e-05	0.0399	CrCbGaD
Levonorgestrel—Mestranol—ESR1—uterine cancer	5.2e-05	0.0389	CrCbGaD
Levonorgestrel—Desogestrel—ESR1—uterine cancer	5.13e-05	0.0384	CrCbGaD
Levonorgestrel—Nandrolone decanoate—CYP19A1—uterine cancer	4.8e-05	0.0359	CrCbGaD
Levonorgestrel—Norgestimate—ESR1—uterine cancer	4.8e-05	0.0359	CrCbGaD
Levonorgestrel—Danazol—PGR—uterine cancer	4.24e-05	0.0317	CrCbGaD
Levonorgestrel—Etonogestrel—ESR1—uterine cancer	4.15e-05	0.0311	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ESR2—uterine cancer	4.02e-05	0.0301	CrCbGaD
Levonorgestrel—Norethindrone—PGR—uterine cancer	3.77e-05	0.0282	CrCbGaD
Levonorgestrel—Danazol—CYP19A1—uterine cancer	2.91e-05	0.0218	CrCbGaD
Levonorgestrel—Testosterone—CYP11A1—uterine cancer	2.76e-05	0.0206	CrCbGaD
Levonorgestrel—Danazol—ESR1—uterine cancer	2.68e-05	0.02	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ESR1—uterine cancer	2.48e-05	0.0185	CrCbGaD
Levonorgestrel—Methyltestosterone—CYP19A1—uterine cancer	2.46e-05	0.0184	CrCbGaD
Levonorgestrel—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	2.21e-05	0.000585	CcSEcCtD
Levonorgestrel—Progesterone—PGR—uterine cancer	2.2e-05	0.0164	CrCbGaD
Levonorgestrel—Dizziness—Progesterone—uterine cancer	2.19e-05	0.000579	CcSEcCtD
Levonorgestrel—Vascular purpura—Epirubicin—uterine cancer	2.16e-05	0.000571	CcSEcCtD
Levonorgestrel—Immune system disorder—Etoposide—uterine cancer	2.15e-05	0.00057	CcSEcCtD
Levonorgestrel—Asthenia—Medroxyprogesterone Acetate—uterine cancer	2.15e-05	0.00057	CcSEcCtD
Levonorgestrel—Eczema—Epirubicin—uterine cancer	2.15e-05	0.000569	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Etoposide—uterine cancer	2.15e-05	0.000568	CcSEcCtD
Levonorgestrel—Abnormal vision—Doxorubicin—uterine cancer	2.15e-05	0.000568	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Dactinomycin—uterine cancer	2.13e-05	0.000564	CcSEcCtD
Levonorgestrel—Pruritus—Medroxyprogesterone Acetate—uterine cancer	2.12e-05	0.000562	CcSEcCtD
Levonorgestrel—Alopecia—Etoposide—uterine cancer	2.11e-05	0.000557	CcSEcCtD
Levonorgestrel—Vomiting—Progesterone—uterine cancer	2.1e-05	0.000557	CcSEcCtD
Levonorgestrel—Rash—Progesterone—uterine cancer	2.09e-05	0.000552	CcSEcCtD
Levonorgestrel—Dermatitis—Progesterone—uterine cancer	2.09e-05	0.000552	CcSEcCtD
Levonorgestrel—Headache—Progesterone—uterine cancer	2.07e-05	0.000549	CcSEcCtD
Levonorgestrel—Increased appetite—Epirubicin—uterine cancer	2.06e-05	0.000544	CcSEcCtD
Levonorgestrel—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	2.05e-05	0.000543	CcSEcCtD
Levonorgestrel—Decreased appetite—Dactinomycin—uterine cancer	2.03e-05	0.000538	CcSEcCtD
Levonorgestrel—Fatigue—Dactinomycin—uterine cancer	2.02e-05	0.000534	CcSEcCtD
Levonorgestrel—Back pain—Etoposide—uterine cancer	2.01e-05	0.000531	CcSEcCtD
Levonorgestrel—Purpura—Epirubicin—uterine cancer	2e-05	0.00053	CcSEcCtD
Levonorgestrel—Pain—Dactinomycin—uterine cancer	2e-05	0.00053	CcSEcCtD
Levonorgestrel—Vascular purpura—Doxorubicin—uterine cancer	2e-05	0.000529	CcSEcCtD
Levonorgestrel—Muscle spasms—Etoposide—uterine cancer	2e-05	0.000528	CcSEcCtD
Levonorgestrel—Eczema—Doxorubicin—uterine cancer	1.99e-05	0.000526	CcSEcCtD
Levonorgestrel—Dizziness—Medroxyprogesterone Acetate—uterine cancer	1.98e-05	0.000525	CcSEcCtD
Levonorgestrel—Nausea—Progesterone—uterine cancer	1.97e-05	0.00052	CcSEcCtD
Levonorgestrel—Pain in extremity—Epirubicin—uterine cancer	1.93e-05	0.000511	CcSEcCtD
Levonorgestrel—Anaemia—Etoposide—uterine cancer	1.92e-05	0.000508	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Dactinomycin—uterine cancer	1.91e-05	0.000506	CcSEcCtD
Levonorgestrel—Vomiting—Medroxyprogesterone Acetate—uterine cancer	1.91e-05	0.000505	CcSEcCtD
Levonorgestrel—Increased appetite—Doxorubicin—uterine cancer	1.9e-05	0.000503	CcSEcCtD
Levonorgestrel—Affect lability—Epirubicin—uterine cancer	1.9e-05	0.000503	CcSEcCtD
Levonorgestrel—Migraine—Epirubicin—uterine cancer	1.9e-05	0.000503	CcSEcCtD
Levonorgestrel—Rash—Medroxyprogesterone Acetate—uterine cancer	1.89e-05	0.000501	CcSEcCtD
Levonorgestrel—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	1.89e-05	0.0005	CcSEcCtD
Levonorgestrel—Headache—Medroxyprogesterone Acetate—uterine cancer	1.88e-05	0.000497	CcSEcCtD
Levonorgestrel—Vertigo—Etoposide—uterine cancer	1.86e-05	0.000493	CcSEcCtD
Levonorgestrel—Purpura—Doxorubicin—uterine cancer	1.85e-05	0.000491	CcSEcCtD
Levonorgestrel—Abdominal pain—Dactinomycin—uterine cancer	1.85e-05	0.000489	CcSEcCtD
Levonorgestrel—Body temperature increased—Dactinomycin—uterine cancer	1.85e-05	0.000489	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—CTNNB1—uterine cancer	1.85e-05	0.00109	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—SUZ12—uterine cancer	1.84e-05	0.00109	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—EP300—uterine cancer	1.84e-05	0.00109	CbGpPWpGaD
Levonorgestrel—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	1.83e-05	0.00108	CbGpPWpGaD
Levonorgestrel—Mood swings—Epirubicin—uterine cancer	1.83e-05	0.000484	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—CDKN1B—uterine cancer	1.83e-05	0.00108	CbGpPWpGaD
Levonorgestrel—Loss of consciousness—Etoposide—uterine cancer	1.82e-05	0.000483	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—PIK3CA—uterine cancer	1.82e-05	0.00108	CbGpPWpGaD
Levonorgestrel—Cough—Etoposide—uterine cancer	1.81e-05	0.000479	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—ERBB2—uterine cancer	1.81e-05	0.00107	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	1.81e-05	0.00107	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	1.8e-05	0.00107	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—PTEN—uterine cancer	1.8e-05	0.00106	CbGpPWpGaD
Levonorgestrel—Hypertension—Etoposide—uterine cancer	1.79e-05	0.000474	CcSEcCtD
Levonorgestrel—Pain in extremity—Doxorubicin—uterine cancer	1.79e-05	0.000473	CcSEcCtD
Levonorgestrel—Nausea—Medroxyprogesterone Acetate—uterine cancer	1.78e-05	0.000472	CcSEcCtD
Levonorgestrel—Dry skin—Epirubicin—uterine cancer	1.77e-05	0.000468	CcSEcCtD
Levonorgestrel—Chest pain—Etoposide—uterine cancer	1.77e-05	0.000467	CcSEcCtD
Levonorgestrel—Affect lability—Doxorubicin—uterine cancer	1.76e-05	0.000465	CcSEcCtD
Levonorgestrel—Migraine—Doxorubicin—uterine cancer	1.76e-05	0.000465	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	1.75e-05	0.000464	CcSEcCtD
Levonorgestrel—Discomfort—Etoposide—uterine cancer	1.75e-05	0.000462	CcSEcCtD
Levonorgestrel—Breast disorder—Epirubicin—uterine cancer	1.75e-05	0.000462	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—CTNNB1—uterine cancer	1.73e-05	0.00102	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Dactinomycin—uterine cancer	1.72e-05	0.000456	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—STK11—uterine cancer	1.72e-05	0.00102	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—CYP19A1—uterine cancer	1.72e-05	0.00102	CbGpPWpGaD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—EP300—uterine cancer	1.72e-05	0.00102	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—EP300—uterine cancer	1.72e-05	0.00102	CbGpPWpGaD
Levonorgestrel—ESR1—LKB1 signaling events—TP53—uterine cancer	1.69e-05	0.001	CbGpPWpGaD
Levonorgestrel—Mood swings—Doxorubicin—uterine cancer	1.69e-05	0.000448	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—FGFR2—uterine cancer	1.69e-05	0.000998	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—HRAS—uterine cancer	1.68e-05	0.000995	CbGpPWpGaD
Levonorgestrel—Infection—Etoposide—uterine cancer	1.68e-05	0.000445	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—PTEN—uterine cancer	1.68e-05	0.000994	CbGpPWpGaD
Levonorgestrel—Abdominal distension—Epirubicin—uterine cancer	1.68e-05	0.000445	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—ESR2—uterine cancer	1.68e-05	0.000993	CbGpPWpGaD
Levonorgestrel—Asthenia—Dactinomycin—uterine cancer	1.68e-05	0.000444	CcSEcCtD
Levonorgestrel—AR—Gene Expression—CHD4—uterine cancer	1.68e-05	0.000991	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—CDKN1B—uterine cancer	1.67e-05	0.000989	CbGpPWpGaD
Levonorgestrel—Asthma—Epirubicin—uterine cancer	1.67e-05	0.000442	CcSEcCtD
Levonorgestrel—Influenza—Epirubicin—uterine cancer	1.67e-05	0.000442	CcSEcCtD
Levonorgestrel—Skin disorder—Etoposide—uterine cancer	1.64e-05	0.000435	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CDH1—uterine cancer	1.64e-05	0.00097	CbGpPWpGaD
Levonorgestrel—Dry skin—Doxorubicin—uterine cancer	1.64e-05	0.000433	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Etoposide—uterine cancer	1.64e-05	0.000433	CcSEcCtD
Levonorgestrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	1.63e-05	0.000966	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—ESR1—uterine cancer	1.62e-05	0.000959	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.62e-05	0.000956	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	1.62e-05	0.000955	CbGpPWpGaD
Levonorgestrel—Breast disorder—Doxorubicin—uterine cancer	1.61e-05	0.000427	CcSEcCtD
Levonorgestrel—Anorexia—Etoposide—uterine cancer	1.61e-05	0.000427	CcSEcCtD
Levonorgestrel—Bronchitis—Epirubicin—uterine cancer	1.61e-05	0.000425	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—EP300—uterine cancer	1.6e-05	0.000948	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Dactinomycin—uterine cancer	1.6e-05	0.000424	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	1.56e-05	0.000924	CbGpPWpGaD
Levonorgestrel—Dysuria—Epirubicin—uterine cancer	1.56e-05	0.000413	CcSEcCtD
Levonorgestrel—Abdominal distension—Doxorubicin—uterine cancer	1.55e-05	0.000411	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Epirubicin—uterine cancer	1.55e-05	0.000411	CcSEcCtD
Levonorgestrel—Influenza—Doxorubicin—uterine cancer	1.54e-05	0.000409	CcSEcCtD
Levonorgestrel—Asthma—Doxorubicin—uterine cancer	1.54e-05	0.000409	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.54e-05	0.000912	CbGpPWpGaD
Levonorgestrel—Pollakiuria—Epirubicin—uterine cancer	1.54e-05	0.000408	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—PTEN—uterine cancer	1.54e-05	0.000911	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	1.54e-05	0.00091	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	1.54e-05	0.000908	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PHF1—uterine cancer	1.52e-05	0.000898	CbGpPWpGaD
Levonorgestrel—Weight increased—Epirubicin—uterine cancer	1.52e-05	0.000402	CcSEcCtD
Levonorgestrel—Weight decreased—Epirubicin—uterine cancer	1.51e-05	0.0004	CcSEcCtD
Levonorgestrel—Dyspnoea—Etoposide—uterine cancer	1.51e-05	0.0004	CcSEcCtD
Levonorgestrel—Somnolence—Etoposide—uterine cancer	1.51e-05	0.000398	CcSEcCtD
Levonorgestrel—Pneumonia—Epirubicin—uterine cancer	1.5e-05	0.000396	CcSEcCtD
Levonorgestrel—Infestation—Epirubicin—uterine cancer	1.49e-05	0.000394	CcSEcCtD
Levonorgestrel—Infestation NOS—Epirubicin—uterine cancer	1.49e-05	0.000394	CcSEcCtD
Levonorgestrel—Vomiting—Dactinomycin—uterine cancer	1.49e-05	0.000394	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—AKT1—uterine cancer	1.49e-05	0.000879	CbGpPWpGaD
Levonorgestrel—Bronchitis—Doxorubicin—uterine cancer	1.49e-05	0.000393	CcSEcCtD
Levonorgestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	1.48e-05	0.000877	CbGpPWpGaD
Levonorgestrel—Rash—Dactinomycin—uterine cancer	1.48e-05	0.00039	CcSEcCtD
Levonorgestrel—Decreased appetite—Etoposide—uterine cancer	1.47e-05	0.00039	CcSEcCtD
Levonorgestrel—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	1.46e-05	0.000865	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Etoposide—uterine cancer	1.46e-05	0.000387	CcSEcCtD
Levonorgestrel—Fatigue—Etoposide—uterine cancer	1.46e-05	0.000386	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—PGR—uterine cancer	1.45e-05	0.000859	CbGpPWpGaD
Levonorgestrel—Constipation—Etoposide—uterine cancer	1.45e-05	0.000383	CcSEcCtD
Levonorgestrel—Pain—Etoposide—uterine cancer	1.45e-05	0.000383	CcSEcCtD
Levonorgestrel—Urinary tract infection—Epirubicin—uterine cancer	1.45e-05	0.000383	CcSEcCtD
Levonorgestrel—Dysuria—Doxorubicin—uterine cancer	1.44e-05	0.000382	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Doxorubicin—uterine cancer	1.44e-05	0.00038	CcSEcCtD
Levonorgestrel—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	1.43e-05	0.000846	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—EP300—uterine cancer	1.43e-05	0.000843	CbGpPWpGaD
Levonorgestrel—Pollakiuria—Doxorubicin—uterine cancer	1.43e-05	0.000378	CcSEcCtD
Levonorgestrel—Testosterone—CYP19A1—uterine cancer	1.43e-05	0.0107	CrCbGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CDH1—uterine cancer	1.41e-05	0.000834	CbGpPWpGaD
Levonorgestrel—Weight increased—Doxorubicin—uterine cancer	1.41e-05	0.000372	CcSEcCtD
Levonorgestrel—AR—Gene Expression—SUZ12—uterine cancer	1.41e-05	0.000831	CbGpPWpGaD
Levonorgestrel—AR—Coregulation of Androgen receptor activity—AKT1—uterine cancer	1.4e-05	0.00083	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.4e-05	0.000828	CbGpPWpGaD
Levonorgestrel—Weight decreased—Doxorubicin—uterine cancer	1.4e-05	0.00037	CcSEcCtD
Levonorgestrel—Sinusitis—Epirubicin—uterine cancer	1.4e-05	0.00037	CcSEcCtD
Levonorgestrel—Nausea—Dactinomycin—uterine cancer	1.39e-05	0.000368	CcSEcCtD
Levonorgestrel—Progesterone—ESR1—uterine cancer	1.39e-05	0.0104	CrCbGaD
Levonorgestrel—Pneumonia—Doxorubicin—uterine cancer	1.39e-05	0.000367	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Etoposide—uterine cancer	1.38e-05	0.000366	CcSEcCtD
Levonorgestrel—Infestation—Doxorubicin—uterine cancer	1.38e-05	0.000364	CcSEcCtD
Levonorgestrel—Infestation NOS—Doxorubicin—uterine cancer	1.38e-05	0.000364	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—NRAS—uterine cancer	1.37e-05	0.000813	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—CDKN2B—uterine cancer	1.37e-05	0.000808	CbGpPWpGaD
Levonorgestrel—Urticaria—Etoposide—uterine cancer	1.35e-05	0.000356	CcSEcCtD
Levonorgestrel—Haemoglobin—Epirubicin—uterine cancer	1.34e-05	0.000355	CcSEcCtD
Levonorgestrel—Rhinitis—Epirubicin—uterine cancer	1.34e-05	0.000354	CcSEcCtD
Levonorgestrel—Abdominal pain—Etoposide—uterine cancer	1.34e-05	0.000354	CcSEcCtD
Levonorgestrel—Body temperature increased—Etoposide—uterine cancer	1.34e-05	0.000354	CcSEcCtD
Levonorgestrel—Urinary tract infection—Doxorubicin—uterine cancer	1.34e-05	0.000354	CcSEcCtD
Levonorgestrel—Haemorrhage—Epirubicin—uterine cancer	1.34e-05	0.000354	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Epirubicin—uterine cancer	1.33e-05	0.000352	CcSEcCtD
Levonorgestrel—Pharyngitis—Epirubicin—uterine cancer	1.33e-05	0.000351	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Epirubicin—uterine cancer	1.32e-05	0.000349	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Epirubicin—uterine cancer	1.31e-05	0.000347	CcSEcCtD
Levonorgestrel—Urethral disorder—Epirubicin—uterine cancer	1.31e-05	0.000347	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—MTHFR—uterine cancer	1.3e-05	0.000766	CbGpPWpGaD
Levonorgestrel—Sinusitis—Doxorubicin—uterine cancer	1.29e-05	0.000342	CcSEcCtD
Levonorgestrel—ESR1—Gene Expression—CHD4—uterine cancer	1.29e-05	0.000764	CbGpPWpGaD
Levonorgestrel—Visual impairment—Epirubicin—uterine cancer	1.29e-05	0.000341	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—ESR2—uterine cancer	1.28e-05	0.000756	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—CXCL8—uterine cancer	1.28e-05	0.000756	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CDH1—uterine cancer	1.26e-05	0.000747	CbGpPWpGaD
Levonorgestrel—Erythema multiforme—Epirubicin—uterine cancer	1.26e-05	0.000334	CcSEcCtD
Levonorgestrel—Eye disorder—Epirubicin—uterine cancer	1.25e-05	0.00033	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—SMAD3—uterine cancer	1.25e-05	0.000738	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Etoposide—uterine cancer	1.25e-05	0.00033	CcSEcCtD
Levonorgestrel—Haemoglobin—Doxorubicin—uterine cancer	1.24e-05	0.000329	CcSEcCtD
Levonorgestrel—Cardiac disorder—Epirubicin—uterine cancer	1.24e-05	0.000328	CcSEcCtD
Levonorgestrel—Rhinitis—Doxorubicin—uterine cancer	1.24e-05	0.000328	CcSEcCtD
Levonorgestrel—Haemorrhage—Doxorubicin—uterine cancer	1.24e-05	0.000327	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Doxorubicin—uterine cancer	1.23e-05	0.000326	CcSEcCtD
Levonorgestrel—Pharyngitis—Doxorubicin—uterine cancer	1.23e-05	0.000325	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Doxorubicin—uterine cancer	1.22e-05	0.000323	CcSEcCtD
Levonorgestrel—Asthenia—Etoposide—uterine cancer	1.22e-05	0.000322	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Doxorubicin—uterine cancer	1.21e-05	0.000321	CcSEcCtD
Levonorgestrel—Urethral disorder—Doxorubicin—uterine cancer	1.21e-05	0.000321	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	1.21e-05	0.000716	CbGpPWpGaD
Levonorgestrel—Immune system disorder—Epirubicin—uterine cancer	1.21e-05	0.000319	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Epirubicin—uterine cancer	1.2e-05	0.000319	CcSEcCtD
Levonorgestrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	1.2e-05	0.000711	CbGpPWpGaD
Levonorgestrel—Pruritus—Etoposide—uterine cancer	1.2e-05	0.000317	CcSEcCtD
Levonorgestrel—Arrhythmia—Epirubicin—uterine cancer	1.19e-05	0.000316	CcSEcCtD
Levonorgestrel—Visual impairment—Doxorubicin—uterine cancer	1.19e-05	0.000315	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—KRAS—uterine cancer	1.18e-05	0.000699	CbGpPWpGaD
Levonorgestrel—Alopecia—Epirubicin—uterine cancer	1.18e-05	0.000312	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—PTEN—uterine cancer	1.18e-05	0.000698	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	1.18e-05	0.000697	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—SRD5A2—uterine cancer	1.18e-05	0.000695	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—NDUFB11—uterine cancer	1.18e-05	0.000695	CbGpPWpGaD
Levonorgestrel—Mental disorder—Epirubicin—uterine cancer	1.17e-05	0.00031	CcSEcCtD
Levonorgestrel—Erythema multiforme—Doxorubicin—uterine cancer	1.17e-05	0.000309	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—AKR1B10—uterine cancer	1.17e-05	0.00069	CbGpPWpGaD
Levonorgestrel—Malnutrition—Epirubicin—uterine cancer	1.16e-05	0.000308	CcSEcCtD
Levonorgestrel—Erythema—Epirubicin—uterine cancer	1.16e-05	0.000308	CcSEcCtD
Levonorgestrel—Diarrhoea—Etoposide—uterine cancer	1.16e-05	0.000307	CcSEcCtD
Levonorgestrel—Eye disorder—Doxorubicin—uterine cancer	1.16e-05	0.000306	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—TP53—uterine cancer	1.15e-05	0.000678	CbGpPWpGaD
Levonorgestrel—Cardiac disorder—Doxorubicin—uterine cancer	1.15e-05	0.000304	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.15e-05	0.000678	CbGpPWpGaD
Levonorgestrel—Flatulence—Epirubicin—uterine cancer	1.15e-05	0.000303	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.14e-05	0.000675	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.14e-05	0.000675	CbGpPWpGaD
Levonorgestrel—Tension—Epirubicin—uterine cancer	1.14e-05	0.000302	CcSEcCtD
Levonorgestrel—Nervousness—Epirubicin—uterine cancer	1.13e-05	0.000299	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—EP300—uterine cancer	1.13e-05	0.000665	CbGpPWpGaD
Levonorgestrel—Back pain—Epirubicin—uterine cancer	1.13e-05	0.000298	CcSEcCtD
Levonorgestrel—Dizziness—Etoposide—uterine cancer	1.12e-05	0.000296	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—PGR—uterine cancer	1.12e-05	0.000662	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	1.12e-05	0.000662	CbGpPWpGaD
Levonorgestrel—Muscle spasms—Epirubicin—uterine cancer	1.12e-05	0.000296	CcSEcCtD
Levonorgestrel—Immune system disorder—Doxorubicin—uterine cancer	1.12e-05	0.000296	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Doxorubicin—uterine cancer	1.11e-05	0.000295	CcSEcCtD
Levonorgestrel—Arrhythmia—Doxorubicin—uterine cancer	1.1e-05	0.000292	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—EP300—uterine cancer	1.1e-05	0.000648	CbGpPWpGaD
Levonorgestrel—Alopecia—Doxorubicin—uterine cancer	1.09e-05	0.000289	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—PIK3CA—uterine cancer	1.09e-05	0.000643	CbGpPWpGaD
Levonorgestrel—Mental disorder—Doxorubicin—uterine cancer	1.08e-05	0.000287	CcSEcCtD
Levonorgestrel—ESR1—Gene Expression—SUZ12—uterine cancer	1.08e-05	0.00064	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.08e-05	0.000638	CbGpPWpGaD
Levonorgestrel—Vomiting—Etoposide—uterine cancer	1.08e-05	0.000285	CcSEcCtD
Levonorgestrel—Erythema—Doxorubicin—uterine cancer	1.08e-05	0.000285	CcSEcCtD
Levonorgestrel—Malnutrition—Doxorubicin—uterine cancer	1.08e-05	0.000285	CcSEcCtD
Levonorgestrel—Anaemia—Epirubicin—uterine cancer	1.08e-05	0.000284	CcSEcCtD
Levonorgestrel—Rash—Etoposide—uterine cancer	1.07e-05	0.000283	CcSEcCtD
Levonorgestrel—Dermatitis—Etoposide—uterine cancer	1.07e-05	0.000282	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	1.07e-05	0.00063	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.06e-05	0.000628	CbGpPWpGaD
Levonorgestrel—Headache—Etoposide—uterine cancer	1.06e-05	0.000281	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—ERBB2—uterine cancer	1.06e-05	0.000627	CbGpPWpGaD
Levonorgestrel—Flatulence—Doxorubicin—uterine cancer	1.06e-05	0.000281	CcSEcCtD
Levonorgestrel—Tension—Doxorubicin—uterine cancer	1.06e-05	0.000279	CcSEcCtD
Levonorgestrel—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	1.05e-05	0.000621	CbGpPWpGaD
Levonorgestrel—Nervousness—Doxorubicin—uterine cancer	1.05e-05	0.000277	CcSEcCtD
Levonorgestrel—Vertigo—Epirubicin—uterine cancer	1.05e-05	0.000277	CcSEcCtD
Levonorgestrel—Syncope—Epirubicin—uterine cancer	1.04e-05	0.000276	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	1.04e-05	0.000616	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—CDKN2B—uterine cancer	1.04e-05	0.000616	CbGpPWpGaD
Levonorgestrel—Back pain—Doxorubicin—uterine cancer	1.04e-05	0.000275	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—HRAS—uterine cancer	1.04e-05	0.000614	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—VEGFA—uterine cancer	1.04e-05	0.000614	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—AKT1—uterine cancer	1.04e-05	0.000614	CbGpPWpGaD
Levonorgestrel—Muscle spasms—Doxorubicin—uterine cancer	1.03e-05	0.000274	CcSEcCtD
Levonorgestrel—Palpitations—Epirubicin—uterine cancer	1.03e-05	0.000272	CcSEcCtD
Levonorgestrel—Loss of consciousness—Epirubicin—uterine cancer	1.02e-05	0.000271	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—ESR1—uterine cancer	1.02e-05	0.000602	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—PTEN—uterine cancer	1.02e-05	0.0006	CbGpPWpGaD
Levonorgestrel—Cough—Epirubicin—uterine cancer	1.02e-05	0.000269	CcSEcCtD
Levonorgestrel—Nausea—Etoposide—uterine cancer	1.01e-05	0.000266	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—HRAS—uterine cancer	1.01e-05	0.000594	CbGpPWpGaD
Levonorgestrel—Hypertension—Epirubicin—uterine cancer	1e-05	0.000266	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1e-05	0.000593	CbGpPWpGaD
Levonorgestrel—Anaemia—Doxorubicin—uterine cancer	9.95e-06	0.000263	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—AKT1—uterine cancer	9.92e-06	0.000586	CbGpPWpGaD
Levonorgestrel—Myalgia—Epirubicin—uterine cancer	9.9e-06	0.000262	CcSEcCtD
Levonorgestrel—Chest pain—Epirubicin—uterine cancer	9.9e-06	0.000262	CcSEcCtD
Levonorgestrel—Anxiety—Epirubicin—uterine cancer	9.87e-06	0.000261	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—ESR2—uterine cancer	9.86e-06	0.000583	CbGpPWpGaD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	9.83e-06	0.00026	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—CDKN1B—uterine cancer	9.82e-06	0.000581	CbGpPWpGaD
Levonorgestrel—Discomfort—Epirubicin—uterine cancer	9.78e-06	0.000259	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	9.78e-06	0.000578	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—EP300—uterine cancer	9.69e-06	0.000572	CbGpPWpGaD
Levonorgestrel—Vertigo—Doxorubicin—uterine cancer	9.67e-06	0.000256	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—RNF43—uterine cancer	9.67e-06	0.000571	CbGpPWpGaD
Levonorgestrel—Syncope—Doxorubicin—uterine cancer	9.65e-06	0.000255	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—SMAD3—uterine cancer	9.51e-06	0.000562	CbGpPWpGaD
Levonorgestrel—Palpitations—Doxorubicin—uterine cancer	9.51e-06	0.000252	CcSEcCtD
Levonorgestrel—Oedema—Epirubicin—uterine cancer	9.49e-06	0.000251	CcSEcCtD
Levonorgestrel—Loss of consciousness—Doxorubicin—uterine cancer	9.46e-06	0.00025	CcSEcCtD
Levonorgestrel—Infection—Epirubicin—uterine cancer	9.43e-06	0.00025	CcSEcCtD
Levonorgestrel—Cough—Doxorubicin—uterine cancer	9.39e-06	0.000249	CcSEcCtD
Levonorgestrel—Shock—Epirubicin—uterine cancer	9.34e-06	0.000247	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	9.33e-06	0.000551	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	9.33e-06	0.000551	CbGpPWpGaD
Levonorgestrel—Nervous system disorder—Epirubicin—uterine cancer	9.31e-06	0.000246	CcSEcCtD
Levonorgestrel—Hypertension—Doxorubicin—uterine cancer	9.29e-06	0.000246	CcSEcCtD
Levonorgestrel—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	9.22e-06	0.000545	CbGpPWpGaD
Levonorgestrel—Skin disorder—Epirubicin—uterine cancer	9.22e-06	0.000244	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Epirubicin—uterine cancer	9.18e-06	0.000243	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	9.17e-06	0.000542	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—AKT1—uterine cancer	9.17e-06	0.000542	CbGpPWpGaD
Levonorgestrel—Chest pain—Doxorubicin—uterine cancer	9.16e-06	0.000242	CcSEcCtD
Levonorgestrel—Myalgia—Doxorubicin—uterine cancer	9.16e-06	0.000242	CcSEcCtD
Levonorgestrel—Anxiety—Doxorubicin—uterine cancer	9.13e-06	0.000242	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	9.1e-06	0.000241	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—PTEN—uterine cancer	9.09e-06	0.000537	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—KRAS—uterine cancer	9.06e-06	0.000536	CbGpPWpGaD
Levonorgestrel—Discomfort—Doxorubicin—uterine cancer	9.05e-06	0.00024	CcSEcCtD
Levonorgestrel—Anorexia—Epirubicin—uterine cancer	9.05e-06	0.000239	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—PTEN—uterine cancer	9.04e-06	0.000535	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—AKT1—uterine cancer	8.88e-06	0.000525	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—INHBA—uterine cancer	8.84e-06	0.000523	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	8.83e-06	0.000522	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	8.83e-06	0.000522	CbGpPWpGaD
Levonorgestrel—Oedema—Doxorubicin—uterine cancer	8.78e-06	0.000232	CcSEcCtD
Levonorgestrel—Infection—Doxorubicin—uterine cancer	8.73e-06	0.000231	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—EZH2—uterine cancer	8.72e-06	0.000516	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	8.68e-06	0.000513	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—EP300—uterine cancer	8.67e-06	0.000512	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Epirubicin—uterine cancer	8.65e-06	0.000229	CcSEcCtD
Levonorgestrel—Shock—Doxorubicin—uterine cancer	8.64e-06	0.000229	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	8.62e-06	0.00051	CbGpPWpGaD
Levonorgestrel—Nervous system disorder—Doxorubicin—uterine cancer	8.61e-06	0.000228	CcSEcCtD
Levonorgestrel—Insomnia—Epirubicin—uterine cancer	8.59e-06	0.000227	CcSEcCtD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	8.56e-06	0.000506	CbGpPWpGaD
Levonorgestrel—Skin disorder—Doxorubicin—uterine cancer	8.53e-06	0.000226	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—AKR1B1—uterine cancer	8.5e-06	0.000503	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—STAR—uterine cancer	8.5e-06	0.000503	CbGpPWpGaD
Levonorgestrel—Hyperhidrosis—Doxorubicin—uterine cancer	8.49e-06	0.000225	CcSEcCtD
Levonorgestrel—Dyspnoea—Epirubicin—uterine cancer	8.46e-06	0.000224	CcSEcCtD
Levonorgestrel—Somnolence—Epirubicin—uterine cancer	8.44e-06	0.000223	CcSEcCtD
Levonorgestrel—Anorexia—Doxorubicin—uterine cancer	8.37e-06	0.000222	CcSEcCtD
Levonorgestrel—Dyspepsia—Epirubicin—uterine cancer	8.36e-06	0.000221	CcSEcCtD
Levonorgestrel—Decreased appetite—Epirubicin—uterine cancer	8.25e-06	0.000218	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	8.21e-06	0.000485	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Epirubicin—uterine cancer	8.2e-06	0.000217	CcSEcCtD
Levonorgestrel—Fatigue—Epirubicin—uterine cancer	8.18e-06	0.000217	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	8.18e-06	0.000484	CbGpPWpGaD
Levonorgestrel—Constipation—Epirubicin—uterine cancer	8.12e-06	0.000215	CcSEcCtD
Levonorgestrel—Pain—Epirubicin—uterine cancer	8.12e-06	0.000215	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—ESR2—uterine cancer	8.09e-06	0.000478	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	8.09e-06	0.000478	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—NRAS—uterine cancer	8.07e-06	0.000477	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TP53—uterine cancer	8.06e-06	0.000476	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—CDKN2B—uterine cancer	8.03e-06	0.000474	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Doxorubicin—uterine cancer	8e-06	0.000212	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—AKR1C1—uterine cancer	7.96e-06	0.000471	CbGpPWpGaD
Levonorgestrel—Insomnia—Doxorubicin—uterine cancer	7.94e-06	0.00021	CcSEcCtD
Levonorgestrel—Dyspnoea—Doxorubicin—uterine cancer	7.83e-06	0.000207	CcSEcCtD
Levonorgestrel—Somnolence—Doxorubicin—uterine cancer	7.81e-06	0.000207	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	7.8e-06	0.000461	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Epirubicin—uterine cancer	7.76e-06	0.000205	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—ESR1—uterine cancer	7.76e-06	0.000459	CbGpPWpGaD
Levonorgestrel—Dyspepsia—Doxorubicin—uterine cancer	7.73e-06	0.000205	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	7.73e-06	0.000457	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Doxorubicin—uterine cancer	7.64e-06	0.000202	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Doxorubicin—uterine cancer	7.58e-06	0.000201	CcSEcCtD
Levonorgestrel—Fatigue—Doxorubicin—uterine cancer	7.57e-06	0.0002	CcSEcCtD
Levonorgestrel—Urticaria—Epirubicin—uterine cancer	7.54e-06	0.0002	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	7.53e-06	0.000445	CbGpPWpGaD
Levonorgestrel—Constipation—Doxorubicin—uterine cancer	7.51e-06	0.000199	CcSEcCtD
Levonorgestrel—Pain—Doxorubicin—uterine cancer	7.51e-06	0.000199	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	7.51e-06	0.000444	CbGpPWpGaD
Levonorgestrel—Body temperature increased—Epirubicin—uterine cancer	7.5e-06	0.000199	CcSEcCtD
Levonorgestrel—Abdominal pain—Epirubicin—uterine cancer	7.5e-06	0.000199	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—SMAD3—uterine cancer	7.33e-06	0.000433	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PTEN—uterine cancer	7.21e-06	0.000426	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	7.18e-06	0.000425	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Doxorubicin—uterine cancer	7.18e-06	0.00019	CcSEcCtD
Levonorgestrel—AR—Gene Expression—PGR—uterine cancer	7e-06	0.000414	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Epirubicin—uterine cancer	6.99e-06	0.000185	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	6.98e-06	0.000413	CbGpPWpGaD
Levonorgestrel—Urticaria—Doxorubicin—uterine cancer	6.98e-06	0.000185	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—KRAS—uterine cancer	6.94e-06	0.00041	CbGpPWpGaD
Levonorgestrel—Body temperature increased—Doxorubicin—uterine cancer	6.94e-06	0.000184	CcSEcCtD
Levonorgestrel—Abdominal pain—Doxorubicin—uterine cancer	6.94e-06	0.000184	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TP53—uterine cancer	6.93e-06	0.00041	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	6.9e-06	0.000408	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—EP300—uterine cancer	6.87e-06	0.000406	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKR1B10—uterine cancer	6.85e-06	0.000405	CbGpPWpGaD
Levonorgestrel—Asthenia—Epirubicin—uterine cancer	6.81e-06	0.00018	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	6.8e-06	0.000402	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—AKT1—uterine cancer	6.8e-06	0.000402	CbGpPWpGaD
Levonorgestrel—Pruritus—Epirubicin—uterine cancer	6.72e-06	0.000178	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	6.67e-06	0.000395	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—POLD1—uterine cancer	6.67e-06	0.000394	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—EZH2—uterine cancer	6.65e-06	0.000393	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—CDKN2B—uterine cancer	6.58e-06	0.000389	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Epirubicin—uterine cancer	6.5e-06	0.000172	CcSEcCtD
Levonorgestrel—Hypersensitivity—Doxorubicin—uterine cancer	6.47e-06	0.000171	CcSEcCtD
Levonorgestrel—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	6.39e-06	0.000378	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—PIK3CA—uterine cancer	6.38e-06	0.000377	CbGpPWpGaD
Levonorgestrel—Asthenia—Doxorubicin—uterine cancer	6.3e-06	0.000167	CcSEcCtD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	6.3e-06	0.000372	CbGpPWpGaD
Levonorgestrel—Dizziness—Epirubicin—uterine cancer	6.28e-06	0.000166	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—AKR1C1—uterine cancer	6.24e-06	0.000369	CbGpPWpGaD
Levonorgestrel—Pruritus—Doxorubicin—uterine cancer	6.21e-06	0.000164	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TP53—uterine cancer	6.21e-06	0.000367	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—ESR2—uterine cancer	6.16e-06	0.000364	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKR1C3—uterine cancer	6.13e-06	0.000362	CbGpPWpGaD
Levonorgestrel—Vomiting—Epirubicin—uterine cancer	6.04e-06	0.00016	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—SMAD3—uterine cancer	6.01e-06	0.000355	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Doxorubicin—uterine cancer	6.01e-06	0.000159	CcSEcCtD
Levonorgestrel—Rash—Epirubicin—uterine cancer	5.99e-06	0.000158	CcSEcCtD
Levonorgestrel—Dermatitis—Epirubicin—uterine cancer	5.98e-06	0.000158	CcSEcCtD
Levonorgestrel—Headache—Epirubicin—uterine cancer	5.95e-06	0.000157	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—HRAS—uterine cancer	5.9e-06	0.000349	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	5.85e-06	0.000346	CbGpPWpGaD
Levonorgestrel—Dizziness—Doxorubicin—uterine cancer	5.81e-06	0.000154	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	5.79e-06	0.000342	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—YWHAE—uterine cancer	5.7e-06	0.000337	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RNF43—uterine cancer	5.67e-06	0.000335	CbGpPWpGaD
Levonorgestrel—Nausea—Epirubicin—uterine cancer	5.64e-06	0.000149	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	5.64e-06	0.000333	CbGpPWpGaD
Levonorgestrel—Vomiting—Doxorubicin—uterine cancer	5.58e-06	0.000148	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—RRM2—uterine cancer	5.56e-06	0.000329	CbGpPWpGaD
Levonorgestrel—Rash—Doxorubicin—uterine cancer	5.54e-06	0.000147	CcSEcCtD
Levonorgestrel—Dermatitis—Doxorubicin—uterine cancer	5.53e-06	0.000146	CcSEcCtD
Levonorgestrel—Headache—Doxorubicin—uterine cancer	5.5e-06	0.000146	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—FBXW7—uterine cancer	5.46e-06	0.000323	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—DCN—uterine cancer	5.4e-06	0.000319	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PGR—uterine cancer	5.39e-06	0.000319	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	5.31e-06	0.000314	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	5.24e-06	0.00031	CbGpPWpGaD
Levonorgestrel—Nausea—Doxorubicin—uterine cancer	5.22e-06	0.000138	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—AKT1—uterine cancer	5.21e-06	0.000308	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—INHBA—uterine cancer	5.19e-06	0.000307	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	5.14e-06	0.000304	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—EZH2—uterine cancer	5.12e-06	0.000303	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CYP11A1—uterine cancer	5.09e-06	0.000301	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PIK3CA—uterine cancer	5.08e-06	0.0003	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—CDKN2B—uterine cancer	5.02e-06	0.000296	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—ESR1—uterine cancer	4.9e-06	0.00029	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—AKR1C3—uterine cancer	4.81e-06	0.000284	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—STK11—uterine cancer	4.77e-06	0.000282	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—ESR2—uterine cancer	4.75e-06	0.000281	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKR1C1—uterine cancer	4.67e-06	0.000276	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—SMAD3—uterine cancer	4.58e-06	0.000271	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SOCS3—uterine cancer	4.47e-06	0.000264	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	4.34e-06	0.000257	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN2B—uterine cancer	4.28e-06	0.000253	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IGF1R—uterine cancer	4.16e-06	0.000246	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—AKT1—uterine cancer	4.15e-06	0.000245	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SMAD3—uterine cancer	3.91e-06	0.000231	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—CDKN2B—uterine cancer	3.86e-06	0.000228	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—STK11—uterine cancer	3.74e-06	0.000221	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—ESR1—uterine cancer	3.74e-06	0.000221	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FGFR2—uterine cancer	3.73e-06	0.00022	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKR1C3—uterine cancer	3.6e-06	0.000213	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—SMAD3—uterine cancer	3.53e-06	0.000209	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.51e-06	0.000208	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PGR—uterine cancer	3.51e-06	0.000207	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SRD5A2—uterine cancer	3.43e-06	0.000203	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NDUFB11—uterine cancer	3.43e-06	0.000203	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.35e-06	0.000198	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—YWHAE—uterine cancer	3.34e-06	0.000198	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FBXW7—uterine cancer	3.21e-06	0.000189	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ESR1—uterine cancer	3.19e-06	0.000188	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—MTHFR—uterine cancer	2.81e-06	0.000166	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCL2—uterine cancer	2.81e-06	0.000166	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—STK11—uterine cancer	2.8e-06	0.000166	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SOCS3—uterine cancer	2.62e-06	0.000155	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN2B—uterine cancer	2.51e-06	0.000148	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—STAR—uterine cancer	2.48e-06	0.000147	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKR1B1—uterine cancer	2.48e-06	0.000147	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.48e-06	0.000147	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IGF1R—uterine cancer	2.44e-06	0.000144	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ERBB2—uterine cancer	2.34e-06	0.000138	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SMAD3—uterine cancer	2.29e-06	0.000136	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCL8—uterine cancer	2.22e-06	0.000131	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGFR2—uterine cancer	2.19e-06	0.000129	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN1B—uterine cancer	2.17e-06	0.000128	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CTNNB1—uterine cancer	2.05e-06	0.000121	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTEN—uterine cancer	2e-06	0.000118	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—POLD1—uterine cancer	1.95e-06	0.000115	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EP300—uterine cancer	1.9e-06	0.000113	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.82e-06	0.000108	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—VEGFA—uterine cancer	1.8e-06	0.000107	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NRAS—uterine cancer	1.78e-06	0.000105	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—AKT1—uterine cancer	1.77e-06	0.000105	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCL2—uterine cancer	1.65e-06	9.74e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—RRM2—uterine cancer	1.62e-06	9.6e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—DCN—uterine cancer	1.58e-06	9.32e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTEN—uterine cancer	1.56e-06	9.25e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KRAS—uterine cancer	1.53e-06	9.06e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—EP300—uterine cancer	1.49e-06	8.82e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.48e-06	8.78e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CA—uterine cancer	1.41e-06	8.32e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.4e-06	8.29e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB2—uterine cancer	1.37e-06	8.12e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—uterine cancer	1.36e-06	8.05e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—AKT1—uterine cancer	1.35e-06	7.97e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL8—uterine cancer	1.3e-06	7.7e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HRAS—uterine cancer	1.3e-06	7.7e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN1B—uterine cancer	1.27e-06	7.52e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CTNNB1—uterine cancer	1.2e-06	7.1e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTEN—uterine cancer	1.17e-06	6.92e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKT1—uterine cancer	1.15e-06	6.8e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EP300—uterine cancer	1.12e-06	6.6e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CA—uterine cancer	1.1e-06	6.53e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.09e-06	6.46e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—STK11—uterine cancer	1.09e-06	6.46e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VEGFA—uterine cancer	1.06e-06	6.25e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NRAS—uterine cancer	1.05e-06	6.18e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—AKT1—uterine cancer	1.04e-06	6.14e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—AKT1—uterine cancer	9.02e-07	5.33e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KRAS—uterine cancer	9e-07	5.32e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CA—uterine cancer	8.26e-07	4.88e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MTHFR—uterine cancer	8.21e-07	4.85e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—uterine cancer	8e-07	4.73e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HRAS—uterine cancer	7.65e-07	4.52e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKT1—uterine cancer	6.75e-07	3.99e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTEN—uterine cancer	4.57e-07	2.7e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—EP300—uterine cancer	4.36e-07	2.57e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CA—uterine cancer	3.22e-07	1.9e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKT1—uterine cancer	2.63e-07	1.56e-05	CbGpPWpGaD
